Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
J Immunol
; 194(3): 950-9, 2015 Feb 01.
Article
in En
| MEDLINE
| ID: mdl-25539810
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
CTLA-4 Antigen
/
Programmed Cell Death 1 Receptor
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
J Immunol
Year:
2015
Type:
Article